Volume 2 · Supplement 4 · November 2016
ISSN 2055-66-40 – Print
Foreword
| ISSN 2055-66-59 – Online
www.viruseradication.com
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                J Acquir Immune Defic Syndr  Volume 78, Supplement 1, August 15, 2018
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                ПРактИЧеское РукоВодстВо для соВместных меРоПРИятИй.
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Journal of the International AIDS Society, vol. 21 Issue no. 6 e 25142
Weaknesses in care programmes providing anti‐retroviral therapy (ART) persist and are often instigated by late HIV diagnosis and poor linkage to care. We investigated the potential for a home‐based counselling and testin...g (HBCT) campaign to be improved through the optimal timing and enhancement of testing rounds to generate greater health outcomes at minimum cost.
Countries implementing HBCT can reduce costs by optimally timing rounds and generate greater health outcomes through improving linkage, coverage, and retention. Tailoring HBCT campaigns to individual settings can enhance patient outcomes for minimal cost.
https://doi.org/10.1002/jia2.25142
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Editorial Review 
AIDS 2019, 33:1411–1420
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Supplement Article 
www.jaids.com J Acquir Immune Defic Syndr  Volume 78, Supplement 1, August 15, 2018
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Цель этого документа – повысить уровень осознания актуальности приоритетных направлений научных исследований по проблеме ТБ/ВИЧ (то есть по тем направлениям, кот...орые требуют срочного финансирования и внимания ученых), содействовать координации информационно-пропагандистской работы и стимулировать финансирование научных изысканий. Поставленная задача заключается в наращивании темпов осуществления высококачественных и интегрированных вмешательства по борьбе с ТБ/ВИЧ в условиях ограниченных ресурсов. В документе дается описание пересмотренной повестки дня по приоритетным научным вопросам, в основе которой лежат недавно полученные фактические данные по шести ключевым проблемам коинфекции ТБ и ВИЧ.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Vreeman RC et al. Journal of the International AIDS Society 2017, 20(Suppl 3):21497 http://www.jiasociety.org/index.php/jias/article/view/21497 | http://dx.doi.org/10.7448/IAS.20.4.21497
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                AIDS Research and Therapy 2015, 12:12 (24 April 2015)
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                PLOS ONE | DOI:10.1371/journal.pone.0172392 February 16, 2017